Arcellx announces clinical hold for its immagine-1 phase 2 clinical program

-- fda has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- redwood city, calif. , june 19, 2023 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that it has received notification from the u.s. food and drug administration (fda) that a clinical hold has been placed on its cart-ddbcma investigational new drug (ind) for the treatment of patients with relapsed or refractory multiple myeloma (rrmm).
ACLX Ratings Summary
ACLX Quant Ranking